Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Declines By 24.5%

Gain Therapeutics, Inc. (NASDAQ:GANX) was the target of a large decrease in short interest in February. As of February 28th, there was short interest totalling 348,800 shares, a decrease of 24.5% from the February 13th total of 462,200 shares. Based on an average trading volume of 232,700 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.4% of the company’s shares are short sold.

Wall Street Analyst Weigh In

GANX has been the topic of several research reports. Scotiabank initiated coverage on shares of Gain Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price objective on the stock. Roth Mkm reiterated a “buy” rating and issued a $7.00 price objective on shares of Gain Therapeutics in a research note on Tuesday, December 24th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday. Finally, Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $8.20.

Gain Therapeutics Stock Performance

Shares of GANX opened at $2.38 on Wednesday. The company’s fifty day moving average is $2.23 and its 200-day moving average is $2.01. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $4.63. The firm has a market cap of $63.13 million, a price-to-earnings ratio of -2.16 and a beta of 0.14. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of GANX. Sprott Inc. acquired a new position in shares of Gain Therapeutics during the 4th quarter worth $30,000. Benedict Financial Advisors Inc. acquired a new position in Gain Therapeutics in the 4th quarter valued at $35,000. Bridgeway Capital Management LLC acquired a new position in Gain Therapeutics in the 4th quarter valued at $65,000. Northern Trust Corp grew its stake in Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after buying an additional 39,642 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Gain Therapeutics in the 4th quarter valued at $198,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.